The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has announced its confirmed Board officers for 2026, following elections conducted during the organization’s December 2025 Board meeting, marking a notable achievement for the still young global initiative as it advances its role in promoting scientifically sound, human‑relevant alternatives to animal testing in cosmetics safety evaluation, with the newly appointed leadership illustrating both continuity and the increasing sophistication of ICCS as it builds on a year of meaningful advancements and prepares to broaden its influence across regulatory, scientific, and industry spheres worldwide.
ICCS operates at the nexus of science, policy, and cooperative action, uniting varied stakeholders who pursue the shared goal of advancing the worldwide shift toward animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers highlights the organization’s commitment to preserving strategic direction as it navigates an increasingly intricate global landscape, where expectations surrounding ethical research, scientific precision, and regulatory coherence continue to advance.
Leadership continuity and global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Together, the officers form a Board leadership team that spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than advocacy for any single sector. This balance is central to the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Advancing animal-free science through collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment methods, when rigorously designed and validated, are not only ethically favorable but also scientifically stronger. Since its establishment in early 2023, ICCS has sought to show that non-animal approaches can deliver dependable, relevant insights to safeguard both human well-being and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing involvement from regulators worldwide.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS contributed to shaping new methodologies consistent with next generation risk assessment (NGRA), an evolving framework that draws on advanced in vitro, in silico, and exposure-driven strategies. These methods are now widely regarded as fundamental to contemporary toxicology, offering more human-relevant insights while limiting dependence on animal studies. ICCS’ engagement in this field underscores its dedication to promoting both ethical progress and scientific rigor.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A decisive turning point in cosmetics safety oversight
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has long underscored that moving toward animal‑free safety science cannot progress through isolated initiatives; rather, it demands synchronized engagement from industry, academia, regulatory bodies, and civil society. The Board’s makeup embodies this principle by uniting figures who grasp the technical, regulatory, and organizational aspects required to drive meaningful transformation.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair emphasized the vital need to rely on ICCS’ global, multi-stakeholder framework to close the gap between innovation and regulation, ensuring that advances in animal-free science extend beyond the laboratory and evolve into dependable, consistently implemented tools that regulators can trust.
Strengthening foundations for long-term impact
As ICCS moves toward 2026 and the years that follow, the organization aims to reinforce its progress while broadening its influence, and the newly appointed Board leadership is anticipated to guide key priorities that balance scientific aspirations with practical execution, including pinpointing topics that require further direction or consensus, backing the validation and dissemination of emerging methodologies, and promoting global harmonization to minimize fragmentation among regulatory expectations.
Education remains a core element of ICCS’ strategy, as the organization works to provide accessible, science‑based resources and forums for discussion that illuminate the foundations of animal‑free safety science and enable well‑informed decision‑making. This mission becomes particularly crucial in a field where misconceptions or uneven expertise may slow progress, even when the underlying science is strong.
The organization’s structure, which unites top cosmetics and ingredient manufacturers with trade associations, research groups, and animal protection organizations, places it in a distinctive position to address these challenges. This diverse range of perspectives ensures discussions remain balanced, comprehensive, and focused on shared goals rather than narrow priorities.
Based in New York, ICCS remains active as a global initiative that underscores the inherently international landscape of cosmetics research and regulation. As products and ingredients frequently cross national borders, aligning standards and encouraging mutual acceptance of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science around the world.
By confirming its 2026 Board officers, ICCS underscores stability while hinting at ongoing advancement, with its leadership team providing steady direction after a year marked by concrete achievements and the seasoned perspective needed to guide the next stage of transformation; as scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a unifying hub and driving force for animal-free cosmetics safety science is set to become even more influential.
Ultimately, the significance of the 2026 Board elections lies not only in the individuals appointed, but in what their leadership represents: a sustained commitment to collaboration, scientific integrity, and the responsible advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to translate vision into lasting impact, shaping the future of cosmetics safety in a way that aligns ethics, science, and global public trust.
